Physician profile
Michael T Canavan
NPI 1891739991
$1,240.33
in general payments reported to CMS, 2019-2025
13 companies · $16.59 in 2025
The $16.59 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $91.69 · 2021: $32.89 · 2022: $167 · 2023: $520 · 2024: $252 · 2025: $16.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $515.46 | 2023-2024 | Nuzyra |
| Epsfl, LLC | $145.84 | 2023 | |
| Horizon Therapeutics Plc | $104.17 | 2019-2020 | |
| Angiodynamics, INC. | $93.72 | 2022 | |
| Smith+Nephew, INC. | $91.74 | 2020-2022 | |
| Organogenesis INC. | $60.14 | 2023 | Puraply |
| Melinta Therapeutics, LLC | $54.62 | 2019 | |
| Grt US Holding, INC. | $53.04 | 2022 | |
| Averitas Pharma INC. | $50.61 | 2023 | Qutenza |
| Osiris Therapeutics INC. | $24.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $16.59 | 2025 | Purified Cortrophin Gel |
| Heron Therapeutics, INC. | $15.18 | 2021 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Canavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.